Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roxann Clarke

Podiatrist, Foot Surgery New York, NY Doctor of Podiatric Medicine

NPI 1174829923 CMS profile 7896

111 John St Rm 1450, New York, NY 10038

Open in the dashboard

General payments

$4,360

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roxann Clarke of New York, NY is reported in the CMS Open Payments database as having received $4,360 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,635 19
2024 General $588 12
2023 General $315 9
2022 General $220 9
2021 General $590 12
2020 General $800 11
2019 General $211 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roxann Clarke
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Roxann Clarke were reported at $1,635. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Roxann Clarke Podiatrist, Foot Surgery median Middle half National median
2019 $211 $167 $67–$484 $163
2020 $800 $114 $40–$323 $114
2021 $590 $171 $57–$502 $132
2022 $220 $196 $66–$556 $149
2023 $315 $187 $78–$466 $160
2024 $588 $190 $78–$557 $164
2025 $1,635 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,666 19 payments
  2. Averitas Pharma Inc. $698 12 payments
  3. Ortho Dermatologics, a division of Bausch Health US, LLC $249 13 payments
  4. Paratek Pharmaceuticals, Inc. $200 9 payments
  5. Smith+Nephew, Inc. $180 2 payments
  6. Orthofix Medical, Inc. $168 2 payments
  7. GRT US Holding, Inc. $155 1 payment
  8. Alafair Biosciences,Inc. $150 1 payment
  9. KCI USA, Inc $146 1 payment
  10. Wright Medical Technology, Inc. $139 1 payment
  11. Other $609 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,529 71 payments
  2. Travel and Lodging $830 6 payments
Products named General payments · program years 2019–2025
  1. Qutenza $853 13 payments
  2. PROSTEP $836 9 payments
  3. JUBLIA $234 12 payments
  4. AUGMENT INJECTABLE $208 2 payments
  5. NUZYRA $200 9 payments
  6. ORTHOLOC 3DI $199 2 payments
  7. OASIS $180 2 payments
  8. ORTHOLOC 2 LAPIFUSE $168 1 payment
  9. Physio-Stim Osteogenesis Stimulator $153 1 payment
  10. VersaWrap $150 1 payment
  11. Other $2,504 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

65

Median for Podiatry: 160

Drug cost

$1,710

Median for Podiatry: $2,368

Branded share of claims

32.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 19 $644
Ammonium Lactate Generic 25 $547
Ciclopirox Ciclopirox Olamine Brand 21 $520

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $560
$560 — —
JUBLIA
  • Ortho Dermatologics, a division of Bausch Health US, LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record